Regeneron Pharmaceuticals, Inc. announced that following early termination of the Hart-Scott-Rodino waiting period, the company closed the sale of 12 million newly issued shares of Regeneron common stock to the sanofi-aventis Group at a price of $26.00 per share pursuant to its previously announced agreement.
Fox Business